RSS-Feed abonnieren
DOI: 10.1055/s-0036-1597989
Examining Mortality and Rejection in Combined Heart–Lung Transplantations
Publikationsverlauf
29. September 2016
05. Dezember 2016
Publikationsdatum:
22. Januar 2017 (online)
![](https://www.thieme-connect.de/media/thoracic/201705/lookinside/thumbnails/10-1055-s-0036-1597989_164629-1.jpg)
Abstract
Background There is a paucity of data on outcomes related to combined heart–lung transplantations (HLTs). Our objective was to identify variables associated with mortality and rejection in HLT.
Methods The United Network for Organ Sharing database was reviewed for HLT performed between 1993 and 2008. Long-term survivors (survival > 5 years) were compared with short-term survivors (survival < 5 years). Factors associated with rejection were examined. Risk-adjusted multivariable Cox's proportional hazards regression analysis was performed to examine variables associated with mortality and rejection.
Results Multivariable analysis revealed that recipient male gender was associated with mortality at 1 year (hazard ratio [HR]: 1.68, 95% confidence interval [CI]: 1.11–2.54, p = 0.01) and 5 years (HR: 1.41, 95% CI: 1.05–1.89, p = 0.02). Preoperative extracorporeal membrane oxygenation (ECMO) was associated with mortality at 1 year (HR: 7.55, 95% CI: 2.55–22.30, p < 0.01) and 5 years (HR: 3.14, 95% CI: 1.19–8.32, p = 0.02). Preoperative mechanical ventilation (MV) was associated with mortality at 1 year (HR: 3.51, 95% CI: 1.77–6.98, p < 0.01) and at 5 years (HR: 2.70, 95% CI: 1.51–4.85, p < 0.01). Multivariable analysis showed that male gender (HR: 1.78, 95% CI: 1.03–3.09, p = 0.04) and cytomegalovirus (CMV) positivity in the recipient and donor (HR: 3.09, 95% CI: 1.59–6.01, p < 0.01) were associated with rejection. Clinical infection in the donor (HR: 2.05, 95% CI: 1.16–3.61, p = 0.01) was also associated with rejection.
Conclusion Survival was affected by recipient male sex and need for preoperative ECMO or MV. Risk factors for rejection included male sex, CMV positivity in the donor and recipient, and donor with clinical infection.
-
References
- 1 Toyoda Y, Toyoda Y. Heart-lung transplantation: adult indications and outcomes. J Thorac Dis 2014; 6 (08) 1138-1142
- 2 Yusen RD, Christie JD, Edwards LB. , et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. J Heart Lung Transplant 2013; 32 (10) 965-978
- 3 Mastrobuoni S, Dell'Aquila AM, Azcarate PM, Rabago G, Herreros J. Long-term survival (>20 years) following heart transplantation. J Cardiovasc Surg (Torino) 2012; 53 (05) 677-684
- 4 Kilic A, Weiss ES, George TJ. , et al. What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors. Ann Thorac Surg 2012; 93 (03) 699-704
- 5 Taghavi S, Jayarajan S, Komaroff E. , et al. Double-lung transplantation can be safely performed using donors with heavy smoking history. Ann Thorac Surg 2013; 95 (06) 1912-1917 , discussion 1917–1918
- 6 Gutierrez C, Al-Faifi S, Chaparro C. , et al. The effect of recipient's age on lung transplant outcome. Am J Transplant 2007; 7 (05) 1271-1277
- 7 Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant 2014; 14 (02) 438-445
- 8 Sharples LD, Scott JP, Dennis C. , et al. Risk factors for survival following combined heart-lung transplantation. The first 100 patients. Transplantation 1994; 57 (02) 218-223
- 9 Jayarajan SN, Taghavi S, Komaroff E. , et al. Impact of extracorporeal membrane oxygenation or mechanical ventilation as bridge to combined heart-lung transplantation on short-term and long-term survival. Transplantation 2014; 97 (01) 111-115
- 10 Moffatt-Bruce SD, Karamichalis J, Robbins RC, Whyte RI, Theodore J, Reitz BA. Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?. Ann Thorac Surg 2006; 81 (01) 286-291 , discussion 291
- 11 Kaczmarek I, Meiser B, Beiras-Fernandez A. , et al. Gender does matter: gender-specific outcome analysis of 67,855 heart transplants. Thorac Cardiovasc Surg 2013; 61 (01) 29-36
- 12 Demir A, Coosemans W, Decaluwé H. , et al. Donor-recipient matching in lung transplantation: which variables are important?. Eur J Cardiothorac Surg 2015; 47 (06) 974-983
- 13 Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol 2005; 38 (02) 289-297
- 14 Amodio G, Sales de Albuquerque R, Gregori S. New insights into HLA-G mediated tolerance. Tissue Antigens 2014; 84 (03) 255-263
- 15 Rouas-Freiss N, Naji A, Durrbach A, Carosella ED. Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. Transplantation 2007; 84 (1, Suppl): S21-S25
- 16 Lila N, Amrein C, Guillemain R. , et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002; 105 (16) 1949-1954
- 17 da Cunha-Bang C, Sørensen SS, Iversen M. , et al. Factors associated with the development of cytomegalovirus infection following solid organ transplantation. Scand J Infect Dis 2011; 43 (05) 360-365
- 18 Grundy JE, Lui SF, Super M. , et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2 (8603): 132-135
- 19 Hughes D, Hafferty J, Fulton L. , et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol 2008; 41 (02) 92-95
- 20 Delgado JF, Reyne AG, de Dios S. , et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2015; 34 (08) 1112-1119
- 21 Braga JR, Santos IS, McDonald M, Shah PS, Ross HJ. Factors associated with the development of cardiac allograft vasculopathy--a systematic review of observational studies. Clin Transplant 2012; 26 (02) E111-E124
- 22 Paraskeva M, Bailey M, Levvey BJ. , et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11 (10) 2190-2196
- 23 Ruttmann E, Geltner C, Bucher B. , et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006; 81 (10) 1415-1420
- 24 Len O, Gavaldà J, Blanes M. , et al; Spanish Research Network for the Study of Infection in Transplantation. Donor infection and transmission to the recipient of a solid allograft. Am J Transplant 2008; 8 (11) 2420-2425